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There is an important need for better biomarkers to predict left ventricular (LV) remodelling in 76 
dilated cardiomyopathy (DCM). We undertook a comprehensive assessment of cardiac structure 77 
and myocardial composition to determine predictors of remodelling.  78 
 79 
Methods and Results 80 
Prospective study of patients with recent-onset DCM with cardiovascular magnetic resonance 81 
(CMR) assessment of ventricular structure and function, extra-cellular volume (T1 mapping), 82 
myocardial strain, myocardial scar (late gadolinium enhancement) and contractile reserve 83 
(dobutamine-stress). Regression analyses were used to evaluate predictors of change in LV ejection 84 
fraction (LVEF) over 12 months.  85 
 86 
We evaluated 56 participants (34 DCM patients, median LVEF 43 (33-48)%; 22 controls). Absolute 87 
LV contractile reserve predicted change in LVEF (1% increase associated with 0.4% increase in 88 
LVEF at 12 months, p=0.02). Baseline myocardial strain (p=0.39 global longitudinal strain), 89 
interstitial myocardial fibrosis (p=0.41), replacement myocardial fibrosis (p=0.25), and right 90 
ventricular contractile reserve (p= 0.17) were not associated with LV reverse remodelling. There 91 
was a poor correlation between contractile reserve and either LV extra-cellular volume fraction (r= -92 
0.22, p=0.23) or baseline LVEF (r=0.07, p=0.62). Men were more likely to experience adverse LV 93 
remodelling (p=0.01) but age (p=0.88) and ‘disease-modifying’ heart failure medication (beta 94 
blocker p= 0.28, ACE inhibitor p=0.92) did not predict follow-up LVEF. 95 
 96 
Conclusions  97 
Substantial recovery of LV function occurs within 12 months in most patients with recent-onset 98 
DCM. Women had the greatest improvement in LVEF. A low LV contractile reserve measured by 99 





Dilated cardiomyopathy; myocardial remodelling; recovery; dobutamine stress   105 
 106 
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ABBREVIATIONS 108 
CMR; cardiovascular magnetic resonance 109 
DCM; dilated cardiomyopathy  110 
LVEF; left ventricular ejection fraction  111 
HVOL; healthy volunteer 112 
ECV; extracellular volume fraction  113 
SAX; short axis 114 
HLA; horizontal long axis 115 
VLA; vertical long axis  116 
 117 
  118 
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INTRODUCTION 119 
The prognosis of patients with dilated cardiomyopathy (DCM) is variable, with a 5 year mortality 120 
rate of ~20%1, 2, yet a potential reverse remodelling rate of over 20% 3-6. Unfortunately, clinical 121 
variables and indices of LV function measured at rest do not accurately predict the direction or 122 
extent of LV remodelling6-8. As highlighted by recent AHA guidelines9 the identification of 123 
potential responders to therapy versus non responders remains a major unmet need. 124 
 125 
We used cardiovascular magnetic resonance imaging (CMR) not only to provide accurate and 126 
reproducible measurements of cardiac structure and function but also to assess the myocardial 127 
substrate. The ability to predict whether or not LV function will improve, remain unchanged or 128 
deteriorate could inform management, helping some patients to avoid unnecessary device therapies 129 
and others to avoid false hope of recovery. 130 
 131 
Contractile reserve, the ability of the impaired ventricle to respond to a stressor, portends a good 132 
prognosis10, 11. We therefore hypothesised that contractile reserve could predict LV remodelling, 133 
adverse or beneficial, in patients with recent onset DCM. In particular we sought to evaluate the 134 
relative contribution of ejection fraction, biventricular contractile reserve, myocardial strain and 135 
myocardial fibrosis as determinants of myocardial reverse remodelling.  136 
 137 
METHODS 138 
The study was a prospective observational study of patients with recent onset DCM assessed at 139 
baseline and 12 months.  140 
 141 
 142 
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Study cohort, inclusion and exclusion criteria 143 
Dilated cardiomyopathy cohort  144 
Patients with DCM diagnosed within the preceding 1 year who were aged >18 years, in sinus 145 
rhythm and with no contraindications to CMR or dobutamine stress (Supplementary materials) were 146 
recruited from local clinics, a regional network of cardiologists or self-referral from the 147 
Cardiomyopathy UK patient-association via its website. 148 
 149 
Healthy volunteer cohort  150 
A cohort of age and sex matched healthy volunteers (HVOL) was recruited to permit comparison of 151 
the baseline contractile reserve response in DCM patients and normal subjects. These individuals 152 
had no history of medical illness, were not taking regular medication, and did not have evidence of 153 
cardiac structural or functional impairment on CMR scanning.  154 
 155 
All participants gave written informed consent and the study was approved by the regional research 156 
ethics committee.  157 
 158 
CMR protocol 159 
All participants underwent CMR at 3T (Siemens Skyra scanner). Typical imaging parameters for 160 
the CMR protocol are outlined in Supplementary materials. 161 
 162 
Dobutamine assessment of contractile reserve 163 
LV contractile reserve was defined as the absolute difference between baseline LVEF or baseline 164 
myocardial strain and maximum change after peak dobutamine stress. 165 
 166 
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All patients stopped beta blockers for 48 hours prior to the scan. A baseline ECG was performed. 167 
Dobutamine (concentration 1mg/mL) was administered via a peripheral intravenous cannula with 168 
long line extension to the infusion pump located in the control room. Heart rate and blood pressure 169 
was measured at baseline and then every 2 minutes during dobutamine infusion. 170 
 171 
A short-axis (SAX) cine stack was acquired at baseline, and at two doses of dobutamine 172 
(5μg/kg/minute and 10μg/kg/minute; each stage continued for at least 5 minutes) 2. Biventricular 173 
volumes, ejection fraction and LV mass were measured using a semiautomated threshold-based 174 
technique (CMRtools, Cardiovascular Imaging Solutions, London, UK). All volume and mass 175 
measurements were indexed to body surface area and referenced to age and gender based tables12. 176 
Left and right atrial area (LAA, RAA) and ventricular wall thickness were also measured 177 
(Supplementary materials). 178 
 179 
Assessment of interstitial fibrosis 180 
T1-mapping was performed at basal and mid-ventricular short axis levels before and 15 minutes 181 
after a bolus of a gadolinium-based contrast agent (Gadovist, Bayer) (0.1mmol/kg)13. T1 182 
measurements were taken before and, once heart rate had returned to baseline levels, after 183 
dobutamine. A shortened Modified Lock-Locker Imaging (MOLLI) sequence14 was acquired in 11 184 
cardiac-cycle breath-holds. Images were analysed using CMR tools. T1 values were measured in a 185 
well-defined region of interest in the septum avoiding replacement fibrosis, and a circular region in 186 
the blood pool. Haematocrit was measured on the day of the scan and extracellular volume fraction 187 
(ECV) calculated 15. The mean of two ECV measurements was taken.   188 
 189 
Assessment of myocardial strain using cine DENSE imaging 190 
All patients underwent baseline assessment of myocardial strain using a modified cine spiral 191 
DENSE sequence 16, 17. Images were acquired at the mid-ventricular SAX level and two long axis 192 
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planes (horizontal and vertical) at rest and during the 10μg/kg/min dobutamine dose. Images were 193 
analysed and myocardial strain was extracted from the DENSE data using semi-automated 194 
MATLAB (The Mathworks, Natick, MA, USA) post-processing software from the University of 195 
Virginia 18-20. For long axis images line contour and for SAX images, both contour and region of 196 
interest (manually defined between endo- and epicardial borders) analysis was performed. Strain 197 
was then calculated in the segmented areas, generating regional polar-strain/time curves for radial 198 
and circumferential strain and contour strain/time curves for longitudinal strain in two planes and 199 
short axis strain. 200 
 201 
As a post hoc analysis, CMR feature tracking was used as an alternative longitudinal strain analysis 202 
on baseline cine images. The methods and results are presented in Supplementary materials.  203 
 204 
Assessment of replacement myocardial fibrosis 205 
Provided eGFR was >30mL/min/1.73m2, late-gadolinium enhancement (LGE) images were 206 
acquired using a breath hold inversion recovery sequence following 0.1mmol/kg of gadolinium 207 
contrast agent (Gadovist, Bayer), with inversion times optimised to null normal myocardium. 208 
Images were acquired in three long axis planes and short axis levels corresponding to the cine 209 
images. All LGE images were acquired after swapping of the phase encode direction. Mid-wall 210 
myocardial fibrosis was recorded as present if detected in both phase-encoding direction and in two 211 
orthogonal views. The borders of the myocardium were delineated in each short axis slice with 212 
LGE. The enhanced areas were then segmented using the full-width at half maximum technique and 213 
semi-automated software (CMR42, Circle Cardiovascular Imaging Inc). 214 
 215 
Follow up imaging  216 
Patients underwent follow up imaging with CMR at 12 months or focused 3D echocardiography 217 
(Phillips i33, 3d probe X5-1; analysis using the XCELERA software) if there was a contraindication 218 
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to CMR. Evaluation of follow-up imaging data including LVEF was performed blinded to baseline 219 
scan results (i.e. blinded to the time point of the scan).  220 
 221 
Statistical analysis 222 
The sample size calculation was based on the hypothesis that contractile reserve and change in 223 
LVEF from baseline to 12 months are associated. A sample size of 31 was required to achieve 80% 224 
power with a significance level of 5%, for a univariable regression assuming a 0.25% absolute 225 
increase in 12-month LVEF for each unit increase in LVEF during dobutamine infusion (contractile 226 
reserve). The effect size was calculated based on an R2 of 0.2 for the relationship between absolute 227 
contractile reserve and LVEF at 12 months; a conservative estimate given that previous 228 
echocardiographic studies showed a stronger correlation between stress and follow-up LVEF (r 229 
=0.7-0.8)21, 22.  Target recruitment was inflated from 31 to 34 to allow for an expected 10% drop-out 230 
rate.  Sample size calculations were performed using the pwr.f2.test in R for linear regression 231 
models.  232 
 233 
We used univariate and multivariate linear regression analysis to identify predictors of change in 234 
LVEF from baseline to 12 months. Our primary focus was on the capacity of absolute LV 235 
contractile reserve to predict change in LVEF from baseline to 12 months. Reflecting the biological 236 
response, a specific cut off for contractile reserve was not applied (to indicate the presence/absence 237 
of contractile reserve). We expected that change in LVEF would be related to baseline LVEF 238 
because of regression to the mean, therefore our main analyses were adjusted for baseline LVEF.   239 
 240 
To establish the normal range for contractile reserve a healthy volunteer cohort was recruited. 241 
Target recruitment was set at 20 volunteers, which yields 80% power at a 5% significance level, to 242 
detect a 9% difference in baseline contractile reserve between patients and healthy volunteers. 243 
 244 
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At baseline continuous variables were compared using the Mann-Whitney test and categorical 245 
variables using the Fisher test. A p value of <0.05 was considered significant. All analyses were 246 
conducted in R (version 3.3.1).  247 
RESULTS 248 
Cohort size and loss to follow up 249 
We recruited 34 patients with DCM and 32 completed the study. Two patients withdrew from the 250 
study; one developed bladder cancer and one had a family bereavement. In addition, 22 healthy 251 
volunteers were enrolled as control participants. The median time between presentation and 252 
baseline was 113 days (IQR 51-148 days). 253 
 254 
Patient characteristics and comparison of DCM patients with healthy volunteers 255 
Baseline demographics and CMR parameters of the cohort are shown in Table 1. The median age at 256 
enrolment was 52.5 years in DCM patients and 49.0 years in healthy volunteers. 25 (74%) DCM 257 
patients and 15 (68%) healthy volunteers were male.  Median body surface area was similar in 258 
DCM patients and healthy volunteers (2.00 m2 vs 1.89 m2).  259 
 260 
Most patients were in NYHA functional class I/II (n=33, 97%) and were prescribed beta-blockers 261 
(n=27, 79%), either ACE inhibitors or angiotensin 2 receptor blockers (n=30, 88%), diuretics 262 
(n=22, 65%) and a mineralo-corticoid receptor antagonist (n=19, 56%). Two patients had asthma 263 
and one had bradycardia, precluding the use of beta-blockers. Two patients were taking ivabradine, 264 
one due to a contraindication to beta-blockers. One patient was not on any medication due to 265 
personal choice.  266 
 267 
As expected, patients had higher indexed LV end diastolic and end systolic volumes, higher indexed 268 
LV mass, and lower LVEF compared to healthy volunteers (Table 1). Whilst patients had a higher 269 
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overall ECV at LV basal and mid-ventricular levels (Table 1) there was considerable overlap in 270 
ECV between DCM patients and healthy volunteers (Supplementary Figure 3). 271 
 272 
Safety of dobutamine  273 
One patient did not complete the infusion protocol to 10 μg/kg/min due to an abnormal BP 274 
response, and only had a maximal dobutamine dose of 5 μg/kg/min. No other adverse incidents 275 
occurred during or after the administration of dobutamine in the remaining patients. 276 
 277 
Contractile reserve 278 
Amongst DCM patients, the change (absolute units) in LVEF with dobutamine (contractile reserve) 279 
ranged from a fall of 9% to an increase of 23% with a median change of 11%. Amongst healthy 280 
volunteers, none had a fall in LVEF during stress and increase ranged from 1% to 20% with a 281 
median change of 10%. The contractile reserve was similar for patients with DCM and healthy 282 
volunteers (p=0.99) in both univariate or multivariate analyses (Supplementary materials). Among 283 
all study participants, there was no evidence that LV contractile reserve was associated with either 284 
baseline LVEF (Pearson’s correlation r=0.07, p=0.62) or the change in systolic blood pressure 285 
(SBP) with dobutamine (r=0.10, p=0.49) (Supplementary materials). 286 
 287 
LVEF increased to >35% during dobutamine infusion in seven of ten patients with a baseline LVEF 288 
<35%, although all ten subsequently improved LVEF to >35% by 12 months. 289 
 290 
Amongst patients with DCM, the absolute change in RVEF with dobutamine ranged from a fall of 291 
17 units to an increase of 24 units with a median change of 5%. Amongst healthy volunteers, the 292 
range was from a fall of 4% to an increase of 18% with a median of 10.5%. The RV contractile 293 
reserve was similar for patients with DCM and healthy volunteers (p=0.24). RV contractile reserve 294 
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was not correlated with baseline LVEF (r=0.15, p=0.28). However, RV and LV contractile reserves 295 
were highly correlated (r=0.81, p<0.00001). 296 
 297 
Absolute changes in dobutamine-induced global circumferential and radial strain, short-axis contour 298 
strain, and long-axis strains were similar for patients and healthy volunteers (Table 1), with the 299 
exception of horizontal long-axis strain.  300 
 301 
Mechanistic basis of contractile reserve: correlation between contractile reserve and ECV 302 
The ability to assess interstitial fibrosis in-vivo using CMR provides an opportunity to explore the 303 
biological basis of contractile reserve. There was a strong correlation between native T1 304 
measurements before and after dobutamine, both at basal (r=0.96, p<0.00001) and mid-ventricular 305 
(r=0.93, p<0.00001) levels, suggesting that dobutamine does not affect T1 measurements at 3T. 306 
 307 
Contractile reserve was not associated with the amount of interstitial fibrosis in patients with DCM, 308 
measured as basal (r= -0.22, p=0.23) or mid LV ECV (r=-0.24, p=0.19). Whilst the individual with 309 
a very high ECV also had a fall in LVEF with dobutamine, for other patients, there was no clear 310 
relationship between higher ECV and lower contractile reserve, as would be expected if reduced 311 
contractile reserve was a consequence of interstitial fibrosis (Figure 1). Most notably, those with a 312 
fall in LVEF with dobutamine had similar ECV values to those in whom LVEF rose substantially. 313 
In healthy volunteers, despite little variation in ECV, there was wide variation in contractile reserve 314 
and no correlation between these two measures (basal LV ECV r= -0.16, p=0.49; mid LV ECV r=-315 
0.21, p=0.37) (Figure 1).  316 
 317 
Relationship between  LVEF from baseline to 12 months 318 
At 12 months, eight patients (25%) had received a CRT (n=3) and/or an ICD device contra-319 
indicating CMR and therefore had 3D echocardiography assessment of LV function. The median 320 
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absolute change in LVEF between baseline and follow-up (Figure 2) was 13% (range -1% to 47%). 321 
Nineteen patients (59%) had an absolute increase in LVEF of >10%. LVEF improved from a 322 
baseline of 11% to 58% at 12 months in one patient. Only two patients had a fall in LVEF and only 323 
one other patient had no improvement by 12 months. All 10 patients with an initial LVEF <35% 324 
had an LVEF >50% at 12 months. Overall, most patients achieved an LVEF >50% and 5 an LVEF 325 
>60%. 326 
The lack of association between LVEF at baseline and follow-up (r=0.10, p=0.58, ) suggests that 327 
treatment is effective in restoring LVEF even in patients with very low LVEF at baseline. Of 13 328 
patients with an LVEF <40% at baseline, 11 (85%) had at least a 10% improvement in LVEF by 12 329 
months, compared to 8 of 18 (44%) amongst those with LVEF ≥40% at baseline.  330 
 331 
Predictors of change in LVEF 332 
After adjustment for baseline LVEF, contractile reserve was associated with change in resting 333 
LVEF at 12 months. Each percentage point increase in contractile reserve was associated a 0.4% 334 
increase in LVEF (p=0.02, Table 2; Figure 4). Upon inspection of this figure, it can be seen that the 335 
relationship between contractile reserve and LVEF at 12 months was driven to a substantial degree 336 
by a failure of LVEF to improve substantially in 3 of the 4 patients with a negative contractile 337 
reserve measurement (baseline LVEFs 36%, 39%, 44%).  338 
 339 
The change in LVEF during infusion of dobutamine is partly load-dependent. Accordingly, we tried 340 
to assess myocardial strain contractile reserve, which is the change in peak strain induced by 341 
dobutamine. However, this could only be assessed for between 21 and 25 patients due to inadequate 342 
image quality during peak stress and failed to demonstrate a statistically significant relationship 343 
between strain contractile reserve and LVEF at 12 months (Table 2).  344 
 345 
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Several other baseline variables were not significantly associated with follow-up LVEF, including 346 
age, NYHA class, beta-blocker use, mid-wall LGE presence and extent, basal or mid ECV, native 347 
T1, baseline myocardial strain and RV contractile reserve (Table 2). However, LVEF improved 348 
substantially more in women than in men after adjustment for baseline LVEF (Table 2). Contractile 349 
reserve remained a significant predictor of change in LVEF after adjustment for both sex and 350 
baseline LVEF (p=0.044).   351 
 352 
Sensitivity analysis 353 
Findings were broadly similar after adjustment for baseline LVEF. In a model which included both 354 
sex and contractile reserve, both variables remained significantly associated with follow-up LVEF.  355 
Changes in heart rate and functional mitral regurgitation during dobutamine stress did not predict 356 
follow-up LVEF. Adjustment for the time since DCM diagnosis did not affect the association of LV 357 
contractile reserve with follow up LVEF. Finally, we evaluated whether the association between 358 
contractile reserve and follow up LVEF was affected by the presence of LBBB, as LVEF change 359 
may not reflect contractile reserve in patients with LBBB. When the analysis was restricted to the 9 360 
patients with LBBB, contractile reserve was no longer associated with follow up LVEF. Amongst 361 
the remaining DCM patients without LBBB, contractile reserve remained associated with follow up 362 
LVEF (Supplementary Table 1).  363 
 364 
 365 
DISCUSSION  366 
Our study suggests that patients with a lower baseline LVEF, a higher contractile reserve and 367 
women have the largest improvement in LVEF by 12 months. Poor contractile reserve appears to be 368 
a promising marker to detect patients with DCM who are less likely to have favourable LV 369 
remodelling. Conversely, a large contractile reserve suggests that improvement in LVEF may be 370 
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likely. This is the first study to provide a comprehensive CMR assessment of DCM, including 371 
contractile reserve, cardiac structure and function and myocardial tissue characterisation, in order to 372 
evaluate imaging predictors of remodelling. LV contractile reserve was the only imaging marker 373 
that predicted 12-month LVEF in this cohort; resting measurements of LV structure or function and 374 
myocardial strain or fibrosis did not. Contractile reserve was poorly related to the amount of 375 
myocardial fibrosis, suggesting that the fundamental cause of a decline in contractile reserve is 376 
either a reduction in cardiac myocyte contractile function or in the connection between cardiac 377 
myocytes and the collagen infrastructure.  378 
 379 
Previous work in the field of echocardiography has largely focussed on the prognostic capacity of 380 
contractile reserve10, 11, 23-28 though some studies have also evaluated the ability of contractile 381 
reserve to predict LV remodelling in response to medical therapy22, 29, 30 or CRT in heart failure 382 
patients31. In the latter meta-analysis, the presence of contractile reserve in heart failure patients was 383 
associated with a higher chance of CRT response (odds ratio 4.42, 95% confidence interval 2.15–384 
9.07, P < 0.001). The authors concluded that these findings may indicate that patients with 385 
contractile reserve still have myocyte viability, despite decreased LV function, and as such could 386 
respond to CRT with restoration of myocardial function. However this and the preceding studies are 387 
distinct to the focus of this current study. The unique aspect of our study is that we evaluated CMR 388 
assessed contractile reserve in a DCM specific cohort. This is advantageous for a number of 389 
reasons. The overall response to therapies including CRT has been observed to differ between 390 
patients with ischaemic and non-ischaemic aetiologies32. Non ischaemic heart failure encompasses 391 
more than just DCM therefore studying a DCM only cohort enables the results to be more 392 
applicable to DCM patients, instead of extrapolating their management from a broad heart failure 393 
cohort.  It is known that LV remodelling can occur either spontaneously, or in response to medical 394 
therapy or device therapy21. The purpose of our study was to evaluate whether contractile reserve 395 
response at baseline would be predictive of follow up LVEF, but the study was not designed to 396 
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evaluate response to specific treatments. Accordingly, our findings are applicable to a DCM patient 397 
in the early stages of their disease (within the first year), which is often a time at which patients are 398 
anxious for a better understanding of their likely disease course and an important time for decision 399 
making about device therapy. At present our predictors of changes in LVEF are limited. In contrast 400 
to many of the previously reported contractile reserve studies, CMR measurements of left 401 
ventricular function are more accurate and reproducible than echocardiography; this is of particular 402 
importance when it comes to the assessment of contractile reserve using LVEF. In addition, 403 
utilising CMR enabled the simultaneous interrogation of other potentially important imaging 404 
predictors of remodelling, in particular mid wall fibrosis. Furthermore, utilising CMR enabled 405 
advanced tissue characterisation of interstitial fibrosis which permitted a mechanistic study of the 406 
biological basis of contractile reserve. 407 
 408 
Many patients had a remarkable improvement in LVEF and by one year, most patients had an 409 
LVEF >50% and 16% had an LVEF >60%, demonstrating a remarkable LV structural and 410 
functional plasticity even amongst patients with severe LV impairment due to DCM. How much of 411 
the observed recovery was spontaneous and how much reflected the effects of guideline-412 
recommended therapy is unclear. Almost 60% of patients in this study showed an improvement of 413 
LVEF greater than 10%, which is towards the upper limit of previous findings (25-70%) 8, 33-38 414 
perhaps reflecting advances in pharmacological and device therapy. Contractile reserve itself may 415 
not be the underlying mechanism for remodelling, but the presence of LV contractile reserve is at 416 
least a surrogate marker for the potential for ventricular remodelling. Predicting recovery in patients 417 
with recent onset DCM may be very useful for planning future management. All 10 patients with an 418 
initial LVEF <35% improved LV function to move out of current guideline criteria for ICD 419 
implantation. However, this may be very different from predicting recovery in patients with chronic 420 
disease who have been established on guideline-treatments for a year or more.  421 
 422 
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Control individuals and DCM patients did not statistically differ in their overall contractile reserve 423 
response. However, whilst both DCM patients and control individuals had a wide range of positive 424 
contractile reserve responses, a negative contractile reserve (fall in LVEF with dobutamine) was 425 
unique to the DCM patients. Our results were highly influenced by the failure of LVEF to improve 426 
in DCM patients with a negative contractile reserve. Therefore a negative contractile reserve may 427 
be the most informative response and warrants further investigation. 428 
 429 
This study shows that imaging predictors of outcome in DCM, such as mid-wall replacement 430 
fibrosis (both presence and extent) and RV contractile reserve11, are not strongly related to LV 431 
remodelling, indicating that such measurements are not interchangeable. This suggests that 432 
contractile reserve may reflect the global capacity of the myocardium to remodel whereas LGE 433 
mid-wall fibrosis is a focal insult that does not affect remote myocardial remodelling. However, as 434 
the study was powered to evaluate the association between contractile reserve and left ventricular 435 
functional recovery, we may remain underpowered to detect an association between these other 436 
imaging parameters and functional recovery. For example, though we did not see a consistent 437 
association between global longitudinal strain (GLS) and follow up LVEF in our cohort, there is 438 
limited evidence that GLS can predict a future deterioration in LVEF in patients with apparently 439 
recovered LVEF39.  440 
 441 
Medications that improve prognosis also failed to predict recovery of LVEF, although this may 442 
have been confounded by the duration of therapy, the high prescription of beta-blockers, and the 443 
fact that not all patients had indications to be on guideline directed medical therapy. Once baseline 444 
LVEF was taken into account, men were less likely to demonstrate recovery in LV function.  445 
 446 
There is great interest in exploring the biological basis of recovery of myocardial function40. As 447 
contractile reserve predicts recovery of LV function, its biological basis could provide insights into 448 
Tayal et al, Imaging predictors of remodelling  
    19 
the mechanism of myocardial recovery. Interstitial fibrosis on endomyocardial biopsy has been 449 
inversely linked to the extent of LV contractile reserve41 and myocardial recovery is thought to be 450 
possible if there is both a sufficient mass of viable myocytes and an absence of extensive fibrosis42, 451 
43. Accordingly, we hypothesized that patients with a high ECV (an in vivo estimate of interstitial 452 
fibrosis assessed through CMR T1 mapping) would have diminished contractile reserve. However, 453 
the amount of interstitial fibrosis was poorly related to contractile reserve or recovery of LV 454 
function. This may reflect differing patient populations in previous studies in terms of aetiology or 455 
severity of fibrosis. The lack of correlation with long-term recovery may reflect that interstitial 456 
fibrosis is also a dynamic process that may be reversed with therapy. The biological basis for 457 
contractile reserve is likely to reside in multiple molecular pathways.  458 
 459 
One of the main strengths of this CMR study is the depth of phenotyping with assessment of cardiac 460 
function, interstitial fibrosis, replacement myocardial fibrosis, and myocardial strain in one study, 461 
enabling a comprehensive, state of the art imaging evaluation of potential predictors of LV 462 
remodelling. Another key strength is its prospective study design, with the inclusion of patients 463 
with recent onset DCM (an ‘inception cohort’44). This means that there is no survival bias that can 464 
occur in retrospective cohort studies of LV remodelling, whereby only patients who survived to 465 
remodel have repeated estimates of LV function. This therefore ensures that the estimate of the 466 
proportion of patients who exhibited LV reverse remodelling is also not biased.  467 
 468 
A further important strength in this study is the statistical design and analysis. The study was 469 
adequately powered and no single, arbitrary threshold for left ventricular reverse remodelling 470 
(LVRR) was used. Previous studies have had different definitions of LVRR, with several using an 471 
arbitrary threshold for defining success. Whilst it might aid study design, defining an improvement 472 
in LVEF <10% as failure and >10% as success is less biologically meaningful.  473 
 474 
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Study Limitations 475 
We evaluated contractile reserve using dobutamine; others have used exercise stress 45 and invasive 476 
methods46. Exercise stress depends on the voluntary effort of the patient. Both exercise and invasive 477 
measurements are challenging during CMR.  478 
 479 
Patients with a lower baseline LVEF might be expected to have a greater increase in LVEF because 480 
of regression to the mean. However, the strength of this association was much stronger than might 481 
be expected. Moreover, regression to the mean is driven partly by the variability of a measurement 482 
but LVEF by CMR is highly reproducible. The relationship between contractile reserve and change 483 
in LVEF at 12 months was to a large extent driven by the failure of LVEF to improve greatly in 484 
three patients whose LVEF declined during dobutamine infusion. In addition, it is important to 485 
highlight that contractile reserve assessed by change in LVEF did not predict follow up LVEF 486 
amongst patients with LBBB and another marker of contractile reserve may need to be identified in 487 
these patients. We were not powered to detect whether LBBB is a significant modifier of the 488 
association of contractile reserve with change in LVEF.  489 
 490 
Future directions 491 
The study was not designed to evaluate either the prognostic role of contractile reserve in DCM, or 492 
whether the observed recovery was dependent on continuing pharmacological therapy (remission) 493 
or whether treatment could be withdrawn without further relapse (cure)47. A crucial unanswered 494 
question is whether recovery of LV function indicates a normal prognosis for a patient who has 495 
been diagnosed with DCM or whether, once someone has been diagnosed with DCM the prognosis 496 
remains impaired even if LV function appears to have normalised. The value of assessing 497 
contractile reserve after patients have received months or years of guideline-recommended therapy, 498 
with or without recovery of LVEF also needs to be considered; should it be used to select patients 499 
for more intense pharmacological interventions or novel therapies. Also, restoration of LVEF may 500 
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be an inadequate test for true normalisation of LV function which may require more sophisticated 501 
assessments, such as evaluation of myocardial strain or diffusion tensor imaging. 502 
 503 
 504 
Conclusion  505 
In this cohort of patients with recent-onset DCM, substantial recovery of LV function within 12 506 
months was observed in the majority of cases. LVEF had risen to >50% for most patients by 12 507 
months. The lack of association between LVEF at baseline and follow-up suggests that treatment is 508 
effective in restoring LVEF even in patients with very low LVEF at baseline. A low LV contractile 509 
reserve measured by dobutamine-stress CMR may have additional value in identifying patients 510 
whose LVEF is less likely to recover. 511 
  512 
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Central Illustration Legend: LVEF change at 1 year. Figure shows baseline LVEF (blue dots) and 681 
follow up LVEF (red dots) after 1 year for each of the 32 DCM patients. Most patients showed 682 
improvement in LVEF, with only 2 patients showing a deterioration in LVEF on follow up imaging. 683 
Dotted lines show the LVEF 35%, 45%, 50%, and 60% cut offs. ‘CRT’ indicates which patients 684 
had CRT during follow up. ‘F’ indicates female patients. Left ventricular contractile reserve 685 
assessed through low dose dobutamine stress CMR was the only imaging predictor of ventricular 686 
remodelling in this cohort, suggesting it could be used to identify patients whose LVEF is less 687 






Figure 1: Contractile reserve and ECV. The graph shows that there is no clear relationship between 694 
ECV (left y axis for basal and right y axis for mid LV levels) and absolute contractile reserve (% 695 
unit change in LVEF after peak dobutamine infusion, x axis) in either DCM patients (left plot) or 696 
healthy volunteers (right plot).  697 
 698 
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Figure 2: LVEF change at 1 year. Figure shows baseline LVEF (blue dots) and follow up LVEF (red dots) after 1 year for each of the 32 DCM 
patients. Most patients showed improvement in LVEF, with only 2 patients showing a deterioration in LVEF on follow up imaging. Dotted lines 
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Figure 3: Scatter diagram showing relationship between baseline LVEF and LVEF at 12 months 
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Figure 4: Scatter diagram showing relationship between contractile reserve at baseline and LVEF at 
12 months. *Adjusted for baseline LVEF
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TABLES 
 
Table 1: Baseline demographics and CMR findings in cohort stratified by diagnosis. Continuous data are shown as median (interquartile range) and 
compared using the Mann-Whitney test, categorical data are shown as count (percentages) and compared using Fisher’s exact test. LV/RV=left/right 
ventricular; EF=ejection fraction; EDVi/ESVi=indexed end diastolic/end systolic volume; LVMi=indexed LV mass; LAA/RAA=left/right atrial area; 







Age at baseline 52.5 (45.0 to 60.0) 49.0 (36.0 to 55.0) 0.097 
Sex   0.77 
F 9 (26.5%) 7 (31.8%)  
M 25 (73.5%) 15 (68.2%)  
Body surface area, m2 2.00 (1.78 to 2.21) 1.89 (1.77 to 2.09) 0.28 
Body mass index (kg/m2) 28.0 [23.9, 32.6] 25.1 [24.1, 26.1]   0.036 
Haematocrit 0.41 [0.39, 0.45] 0.43 [0.41, 0.44] 0.24 
LBBB 9 (26.5%) 0 (0.0%) 0.0084 
Systolic BP, mmHg 122.0 (110.0 to 134.0) 111.5 (102.0 to 118.0) 0.0047 
Resting heart rate, bpm 62.5 (57.0 to 73.0) 62.0 (54.0 to 68.0) 0.37 
NYHA class   <0.0001 
I 16 (47.1%) 22 (100.0%)  
II 17 (50.0%) 0 (0.0%)  
III 1 (2.9%) 0 (0.0%)  
LVEDVi, mL/m2 119.6 (108.5 to 143.2) 85.0 (76.7 to 90.0) <0.0001 
LVESVi, mL/m2 65.0 (57.0 to 92.0) 27.5 (23.0 to 33.0) <0.0001 
LVMi, g/m2 82.5 (65.0 to 90.0) 61.5 (47.0 to 71.0) 0.0008 
LVEF at baseline (%) 43.0 (33.0 to 48.0) 67.0 (62.0 to 70.0) <0.0001 
RVEDVi, mL/m2 92.6 (81.8 to 106.6) 91.1 (82.2 to 100.5) 0.48 
RVESVi, mL/m2 45.4 (39.8 to 57.5) 36.6 (29.4 to 44.8) 0.0015 
RVEF, % 49.0 (46.0 to 53.0) 58.5 (53.0 to 63.0) <0.0001 
Presence of midwall LGE 16 (48.5%) 0 (0.0%) <0.0001 
LAA, cm2 26.3 (21.0 to 29.9) 22.5 (20.4 to 26.7) 0.11 
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RAA, cm2 22.9 (20.4 to 26.6) 25.6 (21.2 to 29.4) 0.21 
Maximum LV wall thickness, mm 11.5 (10.0 to 13.0) 9.0 (8.0 to 10.0) 0.0008 
Lateral wall thickness, mm 7.0 (5.0 to 8.0) 6.0 (5.0 to 6.0) 0.066 
Septal wall thickness, mm 9.0 (8.0 to 10.0) 7.3 (6.0 to 8.0) <0.0001 
Septal native T1, ms 1345 (1321 to 1379) 1278 (1261 to 1300) <0.001 
Basal ECV 0.29 (0.26 to 0.31) 0.24 (0.23 to 0.26) 0.0004 
Mid septal ECV 0.28 (0.26 to 0.31) 0.25 (0.24 to 0.27) 0.0042 
SAX contour strain -0.09 (-0.12 to -0.07) -0.16 (-0.18 to -0.14) <0.0001 
HLA contour strain -0.09 (-0.11 to -0.07) -0.16 (-0.16 to -0.14) <0.0001 
VLA contour strain -0.09 (-0.11 to -0.08) -0.15 (-0.16 to -0.14) <0.0001 
Radial strain 0.17 (0.09 to 0.25) 0.41 (0.37 to 0.50) <0.0001 
Circumferential strain -0.10 (-0.12 to -0.08) -0.17 (-0.19 to -0.17) <0.0001 
Strain reserve:    
SAX contour response -0.01 (-0.02 to 0.01) -0.01 (-0.04 to -0.00) 0.11 
HLA contour response 0.01 (-0.01 to 0.02) -0.02 (-0.03 to -0.01) 0.0008 
VLA contour response 0.00 (-0.02 to 0.01) -0.01 (-0.02 to -0.00) 0.16 
Radial response 0.01 (-0.03 to 0.13) 0.10 (-0.02 to 0.21) 0.23 
Circumferential response -0.01 (-0.03 to 0.00) -0.02 (-0.05 to -0.00) 0.35 
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Table 2: Association of patient characteristics with change in LVEF from baseline to 12 months, adjusted for baseline LVEF 
Variable Comparison 
Number of patients 
with measurement Estimated effect on LVEF (%) P-value 
     
Baseline variables     
Age Per decade older 32 -0.2 (-2.8 to 2.4) 0.88 
Female sex Vs. male 32 7.5 (1.7 to 13.3) 0.012 
Beta-blocker use Vs. no use 32 3.8 (-3.3 to 10.9) 0.28 
Beta-blocker dose Per 1 unit higher 26 -0.1 (-1.8 to 1.6) 0.89 
ACE inhibitor Vs. no use 32 -0.4 (-7.3 to 6.6) 0.92 
ACE inhibitor dose  Per 1 unit higher 24 0.3 (-0.4 to 1.0) 0.44 
Aldosterone antagonist use Vs. no use 31 1.4 (-4.7 to 7.6) 0.64 
Aldosterone antagonist dose Per 1 unit higher 19 0.1 (-0.5 to 0.6) 0.83 
LBBB Presence vs absence 32 -1.0 (-7.6 to 5.7) 0.77 
NYHA class  Class II Vs class I  2.7 (-3.0 to 8.3) 0.069 
 Class III Vs class I  16.0 (0.7 to 31.3)  
Presence of midwall LGE Vs absence 31 -3.2 (-8.9 to 2.4) 0.25 
Extent of LGE % (5 Standard Deviations) Per 1% higher  16 0.0 (-1.0 to 1.1) 0.96 
Extent of LGE % (FWHM – full width at 
half maximum) 
Per 1% higher  16 0.2 (-0.6 to 1.0) 0.61 
Mid ECV Per 0.1 higher 31 -2.3 (-8.0 to 3.4) 0.42 
Basal ECV Per 0.1 higher 30 -3.0 (-8.3 to 2.2) 0.24 
Basal native T1 (pre dobutamine) Per 10ms higher 32 0.0 (-0.3 to 0.3) 0.87 
Mid native T1 (pre dobutamine) Per 10ms higher 31 -0.0 (-0.4 to 0.4) 0.87 
SAX contour strain Per 0.1 higher 28 -3.8 (-12.5 to 4.9) 0.38 
HLA strain Per 0.1 higher 29 -2.2 (-7.3 to 3.0) 0.39 
VLA strain Per 0.1 higher 27 3.1 (-7.4 to 13.6) 0.54 
Radial strain Per 0.1 higher 26 1.0 (-0.9 to 2.9) 0.29 
Circumferential strain  Per 0.1 higher 26 -3.7 (-20.6 to 13.1) 0.65 
     
eResponse under max dobutamine stress     
LV contractile reserve  Per 1% higher 31 0.4 (0.1 to 0.7) 0.020 
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Variable Comparison 
Number of patients 
with measurement Estimated effect on LVEF (%) P-value 
     
RV contractile reserve  Per 1% higher 31 0.2 (-0.1 to 0.5) 0.17 
SAX contour strain reserve  Per 0.1 higher 25 -2.7 (-6.8 to 1.4) 0.19 
HLA contour strain reserve Per 0.1 higher 21 -3.2 (-8.7 to 2.3) 0.24 
VLA contour strain reserve Per 0.1 higher 22 -6.3 (-12.8 to 0.1) 0.054 
Radial strain reserve Per 0.1 higher 22 -0.6 (-3.1 to 1.8) 0.59 
Circumferential strain reserve  Per 0.1 higher 22 2.2 (-9.5 to 13.8) 0.70 
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‘Take home figure’ 
Figure 2 
 
One –Sentence summary  
A low LV contractile reserve measured by dobutamine-stress CMR may have additional value in 
identifying dilated cardiomyopathy patients whose LVEF is less likely to recover. 
